Tadalafil
Product Images NDC 50090-4276

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-4276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904276)

Tadalafil 5 mg tablet bottle label from A-S Medication Solutions. The label includes the product name Tadalafil, strength 5 mg, quantity of 90 tablets, storage instructions at 68 to 77 degrees F, and product NDC 50090-4276-0. It also mentions the dosage form as an 80 film-coated tablet.*

FDA Label Image

Tadalafil-fig1 (Tadalafil Fig1)

Four line graphs showing mean maximal change in blood pressure (Tadalafil minus placebo) over time in hours. The graphs represent standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, with time points at 0, 4, 8, 24, 48, 72, and 96 hours after the last dose of Tadalafil 20 mg or placebo.*

FDA Label Image

Tadalafil-fig2 (Tadalafil Fig2)

This image contains two line graphs showing the mean change from baseline in systolic blood pressure over 24 hours. One graph displays the standing systolic blood pressure change and the other shows the supine systolic blood pressure change. Both compare Tadalafil 20 mg combined with doxazosin 8 mg to placebo combined with doxazosin 8 mg over time post-dose in hours.*

FDA Label Image

Tadalafil-fig3 (Tadalafil Fig3)

A line graph depicting the mean change from time-matched baseline in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, combined with 8 mg qd doxazosin. Four data series are shown: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00, illustrating blood pressure variations over time.*

FDA Label Image

Tadalafil-fig4 (Tadalafil Fig4)

A pharmacokinetic graph showing plasma tadalafil concentration (mg/L) over time (hours) for Tadalafil. It compares plasma levels after a single 20 mg dose, a single 5 mg dose, and once-daily 5 mg doses over five consecutive days, including error bars representing standard deviation.*

FDA Label Image

Tadalafil-fig5.jpg (Tadalafil Fig5)

A line graph showing mean IPSS score changes in BPH patients over 12 weeks, comparing Tadalafil 5 mg with placebo. The graph plots change from baseline across treatment duration, indicating greater symptom improvement with Tadalafil by week 12, marked by statistical significance (p<0.01).*

FDA Label Image

Tadalafil-fig6.jpg (Tadalafil Fig6)

A line graph depicting mean IPSS changes over 12 weeks in BPH patients from Study K, comparing Tadalafil 5 mg and placebo. The y-axis shows change from baseline in IPSS total score, while the x-axis represents treatment duration in weeks. Tadalafil shows greater score reduction with statistical significance at weeks 4 and 12.*

FDA Label Image

Tadalafil-fig7.jpg (Tadalafil Fig7)

A line graph showing mean total IPSS changes over weeks of therapy in BPH patients taking Tadalafil combined with Finasteride compared to placebo with Finasteride. The x-axis represents weeks (0, 4, 12, 26) and the y-axis shows least squares mean change from baseline, with Tadalafil/Finasteride group showing greater symptom improvement over time. Statistical significance markers (p<0.001, p<0.05) are indicated at several points.*

FDA Label Image

Tadalafil-fig8.jpg (Tadalafil Fig8)

Line graph depicting mean IPSS total score changes from baseline over 12 weeks of treatment in ED/BPH patients, comparing Tadalafil 5 mg and placebo. The graph shows a greater decrease in IPSS score for Tadalafil 5 mg across the study duration, with statistically significant differences indicated at week 12 (p<0.01). The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline in IPSS total score.*

FDA Label Image

Tadalafil-str (Tadalafil Str)

Chemical structure of the active ingredient Tadalafil, showing its molecular arrangement with distinct rings and functional groups, as labeled in the product data from A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.